Table 2. Detection of MRD in children... | American Society of Hematology

Table 2.

Detection of MRD in children with ALL during clinical and morphologic remission and cumulative incidence of ALL relapse

Time of testing	No. of samples tested	% with MRD^*	5-year incidence of relapse (±SE)^†
Time of testing	No. of samples tested	% with MRD^*	MRD-positive	MRD-negative
End of remission induction	165	25.5	43% ± 11%	10% ± 3%
Continuation therapy
Week 14	145	13.8	69% ± 16%	10% ± 3%
Week 32	156	3.8	86% ± 17%	14% ± 4%
Week 56	163	4.3	51% ± 25%	12% ± 4%

Time of testing	No. of samples tested	% with MRD^*	5-year incidence of relapse (±SE)^†
Time of testing	No. of samples tested	% with MRD^*	MRD-positive	MRD-negative
End of remission induction	165	25.5	43% ± 11%	10% ± 3%
Continuation therapy
Week 14	145	13.8	69% ± 16%	10% ± 3%
Week 32	156	3.8	86% ± 17%	14% ± 4%
Week 56	163	4.3	51% ± 25%	12% ± 4%

MRD, minimal residual disease; ALL, acute lymphoblastic leukemia.

Median (range) percentage of bone marrow mononuclear cells expressing leukemia-associated immunophenotypes (Table 1) was 0.06% (range, 0.01% to 19%).

All comparisons, P < .001.